Effect of Rosiglitazone on Peroxisome Proliferator‐Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug–Induced Mitochondrial Dysfunction | Zendy

Patrick Mallon | Zendy; Rebecca Sedwell | Zendy; Gary David Rogers | Zendy; David Nolan | Zendy; Patrick Unemori | Zendy; Jennifer Hoy | Zendy; Katherine Samaras | Zendy; Anthony D. Kelleher | Zendy; Sean Emery | Zendy; David A. Cooper | Zendy; Andrew Carr | Zendy

Open Access

Effect of Rosiglitazone on Peroxisome Proliferator‐Activated Receptor γ Gene Expression in Human Adipose Tissue Is Limited by Antiretroviral Drug–Induced Mitochondrial Dysfunction

Author(s) -

Patrick Mallon,

Rebecca Sedwell,

Gary David Rogers,

David Nolan,

Patrick Unemori,

Jennifer Hoy,

Katherine Samaras,

Anthony D. Kelleher,

Sean Emery,

David A. Cooper,

Andrew Carr

Publication year - 2008

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/593179

Subject(s) - lipoatrophy , rosiglitazone , adipose tissue , peroxisome proliferator activated receptor gamma , peroxisome proliferator activated receptor , endocrinology , medicine , mitochondrial toxicity , agonist , peroxisome , biology , receptor , toxicity , diabetes mellitus , virus , virology , viral load , antiretroviral therapy

Treatment of human immunodeficiency virus (HIV)-1 with thymidine-analogue nucleoside reverse-transcriptase inhibitors (tNRTIs) causes lipoatrophy, mitochondrial toxicity, and lower adipose tissue expression of peroxisome proliferator-activated receptor gamma (PPARgamma [PPARG gene]). Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research